Clinical trial
Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With…
NCT01522443 · Exelixis, Industry · Terminated
Key facts
| NCT number | NCT01522443 |
|---|---|
| Title | Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer |
| Official title | A Phase 3, Randomized, Double-blind, Controlled Trial of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer |
| Acronym | COMET-2 |
| Lead sponsor | Exelixis, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Prostate Cancer, Castration Resistant Prostate Cancer, Pain, Prostatic Neoplasms |
| Intervention type | Drug |
| Interventions | cabozantinib, mitoxantrone, prednisone |
| Enrollment | 119 |
| Start date | Mar 1, 2012 |
| Primary completion | Oct 1, 2014 |
| Completion | Jan 13, 2015 |
| First posted | Jan 31, 2012 |
| Last update posted | May 23, 2018 |
| Countries | Australia, Canada, Ireland, United Kingdom, United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: